Annual CFF
$25.04 M
+$39.74 M+270.37%
December 31, 2023
Summary
- As of February 8, 2025, AVTX annual cash flow from financing activities is $25.04 million, with the most recent change of +$39.74 million (+270.37%) on December 31, 2023.
- During the last 3 years, AVTX annual CFF has fallen by -$19.74 million (-44.08%).
- AVTX annual CFF is now -76.54% below its all-time high of $106.76 million, reached on December 31, 2021.
Performance
AVTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
+$472.00 K+100.00%
September 30, 2024
Summary
- As of February 8, 2025, AVTX quarterly cash flow from financing activities is $0.00, with the most recent change of +$472.00 thousand (+100.00%) on September 30, 2024.
- Over the past year, AVTX quarterly CFF has increased by +$472.00 thousand (+100.00%).
- AVTX quarterly CFF is now -100.00% below its all-time high of $108.61 million, reached on March 31, 2024.
Performance
AVTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$108.14 M
-$10.70 M-9.00%
September 30, 2024
Summary
- As of February 8, 2025, AVTX TTM cash flow from financing activities is $108.14 million, with the most recent change of -$10.70 million (-9.00%) on September 30, 2024.
- Over the past year, AVTX TTM CFF has dropped by -$10.70 million (-9.00%).
- AVTX TTM CFF is now -9.81% below its all-time high of $119.91 million, reached on March 31, 2024.
Performance
AVTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AVTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +270.4% | +100.0% | -9.0% |
| 3 y3 years | -44.1% | -100.0% | +835.7% |
| 5 y5 years | +140.7% | -100.0% | +835.7% |
AVTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.5% | +270.4% | -100.0% | +100.0% | -9.8% | +835.4% |
| 5 y | 5-year | -76.5% | +270.4% | -100.0% | +100.0% | -9.8% | +835.4% |
| alltime | all time | -76.5% | +270.4% | -100.0% | +100.0% | -9.8% | +835.4% |
Avalo Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $108.14 M(-9.0%) |
| Jun 2024 | - | -$472.00 K(-100.4%) | $118.84 M(-0.9%) |
| Mar 2024 | - | $108.61 M(>+9900.0%) | $119.91 M(+378.8%) |
| Dec 2023 | $25.04 M(-270.4%) | $1000.00(-100.0%) | $25.04 M(-0.3%) |
| Sep 2023 | - | $10.70 M(+1688.5%) | $25.12 M(+74.1%) |
| Jun 2023 | - | $598.00 K(-95.7%) | $14.43 M(-1617.1%) |
| Mar 2023 | - | $13.75 M(>+9900.0%) | -$951.00 K(-93.5%) |
| Dec 2022 | -$14.70 M(-113.8%) | $82.00 K(>+9900.0%) | -$14.70 M(-0.0%) |
| Sep 2022 | - | $0.00(-100.0%) | -$14.71 M(-144.6%) |
| Jun 2022 | - | -$14.78 M(<-9900.0%) | $32.94 M(-52.2%) |
| Mar 2022 | - | $0.00(-100.0%) | $68.94 M(-35.4%) |
| Dec 2021 | $106.76 M(+138.4%) | $76.00 K(-99.8%) | $106.76 M(-0.1%) |
| Sep 2021 | - | $47.64 M(+124.5%) | $106.89 M(+80.4%) |
| Jun 2021 | - | $21.22 M(-43.9%) | $59.24 M(-19.4%) |
| Mar 2021 | - | $37.83 M(>+9900.0%) | $73.51 M(+64.1%) |
| Dec 2020 | $44.78 M(+256.6%) | $200.00 K(>+9900.0%) | $44.78 M(+0.1%) |
| Sep 2020 | - | $1000.00(-100.0%) | $44.72 M(-7.3%) |
| Jun 2020 | - | $35.48 M(+290.0%) | $48.23 M(+275.6%) |
| Mar 2020 | - | $9.10 M(+6614.4%) | $12.84 M(+2.2%) |
| Dec 2019 | $12.56 M | $135.50 K(-96.1%) | $12.56 M(-32.4%) |
| Sep 2019 | - | $3.51 M(+3510.8%) | $18.59 M(-1.7%) |
| Jun 2019 | - | $97.20 K(-98.9%) | $18.92 M(+0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $8.82 M(+43.0%) | $18.86 M(+81.3%) |
| Dec 2018 | $10.40 M(+178.4%) | $6.17 M(+60.7%) | $10.40 M(+144.9%) |
| Sep 2018 | - | $3.84 M(>+9900.0%) | $4.25 M(-2264.4%) |
| Jun 2018 | - | $35.50 K(-90.2%) | -$196.30 K(-104.9%) |
| Mar 2018 | - | $363.40 K(+3087.7%) | $3.98 M(+6.5%) |
| Dec 2017 | $3.74 M(-362.1%) | $11.40 K(-101.9%) | $3.74 M(-0.6%) |
| Sep 2017 | - | -$606.60 K(-114.4%) | $3.76 M(-20.7%) |
| Jun 2017 | - | $4.21 M(+3380.4%) | $4.74 M(-1130.9%) |
| Mar 2017 | - | $121.00 K(+245.7%) | -$460.10 K(-67.7%) |
| Dec 2016 | -$1.43 M(-107.3%) | $35.00 K(-90.7%) | -$1.43 M(-107.2%) |
| Sep 2016 | - | $376.10 K(-137.9%) | $19.94 M(+7.4%) |
| Jun 2016 | - | -$992.20 K(+17.4%) | $18.57 M(-1.1%) |
| Mar 2016 | - | -$844.90 K(-103.9%) | $18.77 M(-4.2%) |
| Dec 2015 | $19.60 M(-17.8%) | $21.40 M(-2240.2%) | $19.60 M(-1176.7%) |
| Sep 2015 | - | -$1.00 M(+27.6%) | -$1.82 M(-108.3%) |
| Jun 2015 | - | -$783.50 K(+4858.9%) | $21.81 M(-8.8%) |
| Mar 2015 | - | -$15.80 K(-26.2%) | $23.92 M(+0.2%) |
| Dec 2014 | $23.86 M(+340.5%) | -$21.40 K(-100.1%) | $23.86 M(-0.1%) |
| Sep 2014 | - | $22.63 M(+1608.3%) | $23.88 M(+1810.4%) |
| Jun 2014 | - | $1.32 M(-1873.4%) | $1.25 M(-1773.4%) |
| Mar 2014 | - | -$74.70 K | -$74.70 K |
| Dec 2013 | $5.42 M | - | - |
FAQ
- What is Avalo Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Avalo Therapeutics?
- What is Avalo Therapeutics annual CFF year-on-year change?
- What is Avalo Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly CFF year-on-year change?
- What is Avalo Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Avalo Therapeutics?
- What is Avalo Therapeutics TTM CFF year-on-year change?
What is Avalo Therapeutics annual cash flow from financing activities?
The current annual CFF of AVTX is $25.04 M
What is the all time high annual CFF for Avalo Therapeutics?
Avalo Therapeutics all-time high annual cash flow from financing activities is $106.76 M
What is Avalo Therapeutics annual CFF year-on-year change?
Over the past year, AVTX annual cash flow from financing activities has changed by +$39.74 M (+270.37%)
What is Avalo Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AVTX is $0.00
What is the all time high quarterly CFF for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly cash flow from financing activities is $108.61 M
What is Avalo Therapeutics quarterly CFF year-on-year change?
Over the past year, AVTX quarterly cash flow from financing activities has changed by +$472.00 K (+100.00%)
What is Avalo Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AVTX is $108.14 M
What is the all time high TTM CFF for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM cash flow from financing activities is $119.91 M
What is Avalo Therapeutics TTM CFF year-on-year change?
Over the past year, AVTX TTM cash flow from financing activities has changed by -$10.70 M (-9.00%)